ARS Pharmaceuticals Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
206
- Stock Symbol
-
SPRY
- Investments
-
1
- Share Price
-
$2.96
- (As of Friday Closing)
ARS Pharmaceuticals General Information
Description
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
Contact Information
Website
www.ars-pharma.comCorporate Office
- 11682 El Camino Real
- Suite 300
- San Diego, CA 92130
- United States
Corporate Office
- 11682 El Camino Real
- Suite 300
- San Diego, CA 92130
- United States
ARS Pharmaceuticals Stock Performance
As of 20-Nov-2026, ARS Pharmaceuticals’s stock price is $2.96. Its current market cap is $298M with 101M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.96 | $3.36 | $2.44 - $13.15 | $298M | 101M | 1.82M | -$2.01 |
ARS Pharmaceuticals Financials Summary
As of 30-Sep-2026, ARS Pharmaceuticals has a trailing 12-month revenue of $122M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 381,449 | 961,138 | 820,785 | 284,490 |
| Revenue | 122,136 | 84,278 | 89,149 | 30 |
| EBITDA | (197,246) | (179,448) | (3,083) | (54,365) |
| Net Income | (199,868) | (171,298) | 7,998 | (54,365) |
| Total Assets | 251,484 | 327,652 | 351,153 | 233,188 |
| Total Debt | 121,807 | 96,374 | 0 | 274 |
ARS Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ARS Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
ARS Pharmaceuticals Comparisons
Industry
Financing
Details
ARS Pharmaceuticals Competitors (36)
One of ARS Pharmaceuticals’s 36 competitors is Rigel Pharmaceuticals, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Rigel Pharmaceuticals | Formerly VC-backed | South San Francisco, CA | ||||
| Camurus | Corporation | Lund, Sweden | ||||
| Indivior | Corporate Backed or Acquired | North Chesterfield, VA | ||||
| Tioga Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| BeOne Medicines | Formerly PE-Backed | Beijing, China |
ARS Pharmaceuticals Patents
ARS Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250262173-A1 | Intranasal epinephrine formulations and methods of use | Pending | 19-Feb-2024 | ||
| WO-2022076905-A1 | Alk5 inhibitors, conjugates, and uses thereof | Inactive | 09-Oct-2020 | ||
| WO-2022006340-A1 | Alk5 inhibitors, conjugates, and uses thereof | Inactive | 01-Jul-2020 | ||
| AU-2021300362-A1 | Anti-asgr1 antibody conjugates and uses thereof | Inactive | 01-Jul-2020 | ||
| CA-3183993-A1 | Anti-asgr1 antibody conjugates and uses thereof | Pending | 01-Jul-2020 | A61K47/6803 |
ARS Pharmaceuticals Signals
ARS Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ARS Pharmaceuticals Acquisitions (1)
ARS Pharmaceuticals’s most recent deal was a Merger/Acquisition with Silverback Therapeutics for . The deal was made on 08-Nov-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Silverback Therapeutics | 08-Nov-2022 | Merger/Acquisition | Biotechnology |
ARS Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
ARS Pharmaceuticals FAQs
-
When was ARS Pharmaceuticals founded?
ARS Pharmaceuticals was founded in 2015.
-
Where is ARS Pharmaceuticals headquartered?
ARS Pharmaceuticals is headquartered in San Diego, CA.
-
What is the size of ARS Pharmaceuticals?
ARS Pharmaceuticals has 206 total employees.
-
What industry is ARS Pharmaceuticals in?
ARS Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is ARS Pharmaceuticals a private or public company?
ARS Pharmaceuticals is a Public company.
-
What is ARS Pharmaceuticals’s stock symbol?
The ticker symbol for ARS Pharmaceuticals is SPRY.
-
What is the current stock price of ARS Pharmaceuticals?
As of 20-Nov-2026 the stock price of ARS Pharmaceuticals is $2.96.
-
What is the current market cap of ARS Pharmaceuticals?
The current market capitalization of ARS Pharmaceuticals is $298M.
-
What is ARS Pharmaceuticals’s current revenue?
The trailing twelve month revenue for ARS Pharmaceuticals is $122M.
-
Who are ARS Pharmaceuticals’s competitors?
Rigel Pharmaceuticals, Camurus, Indivior, Tioga Pharmaceuticals, and BeOne Medicines are some of the 36 competitors of ARS Pharmaceuticals.
-
What is ARS Pharmaceuticals’s annual earnings per share (EPS)?
ARS Pharmaceuticals’s EPS for 12 months was -$2.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process